Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Schering-Plough | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Schering-Plough

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Schering-Plough

4Q Revenues: $2.7 billion (+14%)

4Q Earnings: $204 million (+62%)

FY Revenues: $10.6 billion (+11%)

FY Earnings: $1.1 billion (earnings were $269 million FY2005)

Comments: In the quarter, Remicade sales were up 34% to $337 million, Nasonex sales were up 37% to $253 million, Temodar sales grew 18% to $189 million and Clarinex sales were $164 million, up 18%. FY sales (excluding cholesterol joint venture sales) grew 11% versus 2005, with leading prescription products: Remicade up 32%, Nasonex up 28%, Peg-Intron up 11%, Temodar up 20%, and Clarinex/Aerius up 12%. Global cholesterol joint venture sales, which include Vytorin and Zetia, totaled $1.1 billion in the quarter, up 46% from 4Q2005. Schering-Plough does not record sales of its cholesterol joint venture with Merck as the venture is accounted for under the equity method. R&D spending for the quarter increased 33% to $631 million and for the year totaled $2.2 billion, up 17%. During the year, the company received FDA approval of Noxafil Oral Suspension, a novel triazole antifungal agent. Also, Temodal for malignant glioma was approved in Japan; Remicade for ulcerative colitis was approved in the EU; and Suboxone Sublingual Tablets were approved in the EU for opioid dependence.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters